Clinical trial • Phase III • Immunology | Infectious Disease
Clinical trial in Innate immune system modulation | Healthy volunteers
Phase III trial for Innate immune system modulation | Healthy volunteers. None/Not specified-controlled. 12 participants.
Overview
- Trial Therapeutic Area
- Immunology | Infectious Disease
- Trial Disease
- Innate immune system modulation | Healthy volunteers
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 15-02-2024
- First CTIS Authorization Date
- 08-05-2024
Trial design
None/Not specified-controlled Phase III trial across 1 site in Germany.
- Comparator
- None/Not specified
- Target Sample Size
- 12
Recruitment
- Planned Sample Size
- 12
- Recruitment Window Months
- 6
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 12
Germany
- Earliest CTIS Part Ii Submission Date
- 17-04-2024
- Latest Decision Or Authorization Date
- 08-05-2024
- Processing Time Days
- 21
- Number Of Sites
- 1
- Number Of Participants
- 12
Sites
- Site Name
- Rheinische Friedrich-Wilhelms-Universitaet Bonn
- Department Name
- Phase I-Unit, Institute of Clinical Chemistry and Clinical Pharmacology
- Contact Person Name
- Martin Coenen
- Contact Person Email
- phase1-einheit-szb@ukbonn.de
Sponsor
Primary sponsor
- Full Name
- Rheinische Friedrich-Wilhelms-Universitaet Bonn
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Germany
Related trials
Other published trials that may interest you.